Remimazolam for sedation in gastrointestinal endoscopy:A comprehensive review  

作　　者：Dushyant Singh Dahiya Ganesh Kumar Syeda Parsa Manesh Kumar Gangwani Hassam Ali Amir Humza Sohail Saqr Alsakarneh Umar Hayat Sheza Malik Yash R Shah Bhanu Siva Mohan Pinnam Sahib Singh Islam Mohamed Adishwar Rao Saurabh Chandan Mohammad Al-Haddad 

机构地区：[1]Division of Gastroenterology,Hepatology&Motility,The University of Kansas School of Medicine,Kansas City,MO 66160,United States [2]Department of Internal Medicine,Chandka Medical College,Sindh 77280,Pakistan [3]Department of Gastroenterology and Hepatology,University of Arkansas For Medical Sciences,Little Rock,AR 72205,United States [4]Division of Gastroenterology,Hepatology and Nutrition,East Carolina University/Brody School of Medicine,Greenville,NC 27858,United States [5]Department of Surgery,University of New Mexico School of Medicine,Albuquerque,NM 87106,United States [6]Department of Internal Medicine,University of Missouri-Kansas City,Kansas City,MO 64108,United States [7]Department of Internal Medicine,Geisinger Wyoming Valley Medical Center,Wilkes Barre,PA 18711,United States [8]Department of Internal Medicine,Rochester General Hospital,Rochester,NY 14621,United States [9]Department of Internal Medicine,Trinity Health Oakland/Wayne State University,Pontiac,MI 48341,United States [10]Department of Internal Medicine,John H.Stroger Hospital of Cook County,Chicago,IL 60612,United States [11]Department of Internal Medicine,Sinai hospital,Baltimore,MD 21215,United States [12]Department of Hepatology,University of Missouri,Columbia,MO 65211,United States [13]Department of Internal Medicine,Guthrie Robert Packer Hospital,Sayre,PA 18840,United States [14]Division of Gastroenterology and Hepatology,Creighton University School of Medicine,Omaha,NE 68131,United States [15]Division of Gastroenterology and Hepatology,Indiana University School of Medicine,Indianapolis,IN 46202,United States

出　　处：《World Journal of Gastrointestinal Endoscopy》2024年第7期385-395,共11页世界胃肠内镜杂志（英文版）（电子版）

摘　　要：Worldwide,a majority of routine endoscopic procedures are performed under some form of sedation to maximize patient comfort.Propofol,benzodiazepines and opioids continue to be widely used.However,in recent years,Remimazolam is gaining immense popularity for procedural sedation in gastrointestinal(GI)endoscopy.It is an ultra-short-acting benzodiazepine sedative which was approved by the Food and Drug Administration in July 2020 for use in procedural sedation.Remimazolam has shown a favorable pharmacokinetic and pharmacodynamic profile in terms of its non-specific metabolism by tissue esterase,volume of distribution,total body clearance,and negligible drug-drug interactions.It also has satisfactory efficacy and has achieved high rates of successful sedation in GI endoscopy.Furthermore,studies have demonstrated that the efficacy of Remimazolam is non-inferior to Propofol,which is currently a gold standard for procedural sedation in most parts of the world.However,the use of Propofol is associated with hemodynamic instability and respiratory depression.In contrast,Remimazolam has lower incidence of these adverse effects intra-procedurally and hence,may provide a safer alternative to Propofol in procedural sedation.In this comprehensive narrative review,highlight the pharmacologic characteristics,efficacy,and safety of Remimazolam for procedural sedation.We also discuss the potential of Remimazolam as a suitable alternative and how it can shape the future of procedural sedation in gastroenterology.

关 键 词：Remimazolam ENDOSCOPY SEDATION OUTCOMES EFFICACY Safety PHARMACOKINETICS 

分 类 号：R57[医药卫生—消化系统]